Targeted Analyses
We are setting the standard
At Variantyx, we are setting the standard of genome analysis. We are leading the way by offering the most comprehensive diagnostic testing clinically available for a variety of defined disorders. With thorough interrogation of the genome, we have the ability to detect all major clinically relevant variant types from one sample. A single, unified clinical report is generated through phenotype-driven variant evaluation performed by clinical experts.
Using our methodology’s superior analytical and clinical validity, we are providing better overall performance, diagnostic yield and speed of diagnosis. All at lower overall cost.
Our methodology detects unique targeted variants
The targeted disorders we focus on are caused by a wide variety of DNA changes. Many of these, specifically complex structural variants, mitochondrial variants, and tandem repeat expansions, are not detectable by PCR-based panel and exome technologies. This often leads to false negative results and non-diagnostic outcomes.
Pairing WGS with our Genomic Intelligence® proprietary analytical software allows us to detect mitochondrial variants (including large deletions), structural variants of any size, and repeat expansions in 37 different genes – more genes than any other provider.
Our targeted analysis portfolio
Neurology disorders
Genomic Unity® Comprehensive Ataxia Analysis Mitochondrial disorders
Flexible reflex options facilitate first-line testing
First-line testing with Genomic Unity® is the fastest way to reach a clear diagnostic outcome.
Every test is performed on our whole genome platform. Available automatic reflex options enable starting with targeted, insurance-covered testing followed by a full, comprehensive analysis in the event the first test is non-diagnostic.
Learn more about our billing options.